Company profile
Outlook Therapeutics, Inc.
NASDAQ: OTLK · Healthcare · Biotechnology
#838 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
22DFH 16DQ 24GM 24SS 50
v0.1 · 65/100 weight · provisional
↑ market scale, listing tenure · ↓ revenue growth (YoY), operating margin
Methodology →Revenue TTM
-$1.2M
Rev growth YoY (TTM)
-169.4%
Net income (FY)
-$62.4M
Employees
17
as of 2026-08-19
Market cap
$130.9M
as of 2026-08-19
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.4M$1.4M2025
Net income-$62.4M-$62.4M2025
Operating income-$67.1M-$67.1M2025
Total assets$18.6M$18.6M2025
Liabilities$50.8M$50.8M2025
Equity-$32.2M-$32.2M2025
Revenue trend
FY2016 – FY2025 · USD
FY16
FY16
FY17
FY18
FY19
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Outlook Therapeutics, Inc.’s revenue?
Outlook Therapeutics, Inc. booked $1.4M in FY2025 revenue, contracting 83% year over year — slower than 89% of Healthcare companies we track, at a -4416.2% net margin.
Peers · Healthcare
Daxor Corporation——Perspective Therapeutics, Inc.46DBraxia Scientific Corp.——Avenue Therapeutics, Inc.25DWinston Pharmaceuticals, Inc.——Vasamed, Inc.——Neighbors
Middlesex →Key facts
CEORobert Charles Jahr
SectorHealthcare
IndustryBiotechnology
HeadquartersIselin, NJ
ExchangeNASDAQ: OTLK
Employees17
IPO date2016-06-14
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.